U.S. Markets open in 9 hrs 8 mins

Apricus Biosciences, Inc. (APRI)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.6552-0.0648 (-3.7674%)
At close: 3:57PM EDT
People also watch
BIOCETRMANTHPULMIDXG
  • D
    David Harrington
    David Harrington
    From doofus Hiwatt, the $RPRX moron on Joey's little choo choo train that couldn't (ever): "I predicted a couple months back we could hit .30 cents and today we closed at .3085. I also predicted we would go to P3 with Proellex, or go to pinks sheets if decision went south. Well we didn't go to P3 and we have until Sept 30 to avoid pink sheets. In 2010 it took a 1 for 4 reverse split to stay listed. Will history repeat? Anyway here's my post from months back.
    . Yes I'm still long and yes the stock could hit 30 cents like it did in 2009. It now all comes down to FDA guidance on Proellex and I'm betting we go to P3 . It's possible an EU approval could help longs get back their losses, but if Proellex decision goes south, we'll be trading on pink sheets until that vote comes down."
  • D
    David Harrington
    David Harrington
    $RPRX failed where APRICUS will win. I think the resubmission too looks promising but I haven't given up on APRI SERM story.
  • K
    Kylie
    Kylie
    I have a feeling APRI will see a pullback now. What yall think? Im not sure about you guys but awe-some*sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • C
    Clarence
    Clarence
    looks like shorts covered through Wainwright
  • J
    Julia
    Julia
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on APRI before rallying up. have you guys heard of awe-som*sto-cks. i started receiving their allerts and so far i am happy.
  • c
    cahir
    cahir
    What’s the next breakout stock? Check out ExplosiveOTC.com and you will find the best hidden gems before they become the talk of the markets. ExplosiveOTC.com
  • D
    Don
    Don
    Next earning lost -16 cents.
    Be careful.
  • O
    Ophelia
    Ophelia
    2750% Bounce coming with $KOSK stock price ....contracts with medical industry for its vending machines due any day now
  • S
    Shanawaz
    Shanawaz
    APRI - world wide - Great review from users and they are all recommending Vitaros best creme and easy to use. APRI NDA Resubmission data and approval looks very favorable 100%. Apri expecting will be at 3 bucks soon
  • M
    Marinshell
    Marinshell
    A little perky in share price today!?!
  • M
    Mohammad
    Mohammad
    Why Vitaros is approved over 26 countries and still not approved in US ?
  • H
    Harry
    Harry
    I wonder how many people know Allergan has a right to buy rights to Vitaros for $25M upfront, milestone payments and royalties? If that happens the company will easily more than triple in value just based on that upfront payment alone.
  • D
    David Harrington
    David Harrington
    This is looking good today. See $2 soon.
  • D
    David Harrington
    David Harrington
    Looks like the corrupt crackpot legacy of Joey the Dogdoltski reigns with $RPRX latest failure! Pretty remarkable that investors put up with his obvious misleading of investors with his fake and faulty data. The problems continue for Repros. You just cannot undo years of mismanaged studies and negligence. Proellex will never get out of phase 2 ever. Too many safety problems ignored.
  • K
    Kaitlyn
    Kaitlyn
    Is APRI overvalued at current levels? have you guys heard of awe*some*stocks. i started receiving their allerts and so far i am happy.
  • M
    Marinshell
    Marinshell
    What do we learn as far as Corporate Developments today at 4:30 ET!?!
  • A
    Anonymous
    Anonymous
    Patent exipration on VIAGRA until 2020. Patent expiration of CIALIS Nov 2017. TEVA allowed to manufacture generic VIAGRA but have to pay royalty to PFIZER
  • D
    Dave
    Dave
    breakout $1.70++ news tommorow
  • M
    Marinshell
    Marinshell
    Interesting to note: Pfizer patent on Viagra is expiring this fall - open to generics and competition. Perhaps APRI may factor into Pfizer next steps for the ED market?